MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$12,248K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-12,888 -29,447
Stock-based compensation
3,976 3,035
Non-cash operating lease expense
56 88
Accretion of discounts on marketable securities, net
523 1,240
Depreciation and amortization expense
29 38
In-process research and development, related party
0 0
Unrealized foreign currency transaction (gain) loss
1 -24
Prepaid expenses and other current assets
1,382 -1,272
Other long-term assets
162 1,352
Accounts payable
-393 165
Accounts payable and accrued liabilities, related party-Related Party
0 0
Accrued expenses and other current liabilities
-792 944
Operating lease liabilities
-59 -109
Long-term liabilities
0 0
Net cash used in operating activities
-12,139 -26,582
Purchases of property and equipment
109 77
Purchases of marketable securities
23,712 79,370
Maturities of marketable securities
39,081 41,482
Issuance of promissory loan in connection with asset acquisition
0 0
Cash paid in connection with asset acquisition, net of cash received
0 0
Net cash used in investing activities
15,260 -37,965
Proceeds from exercise of stock options
0 0
Proceeds from issuance of common stock in private placement, net of issuance costs
0 0
Net cash provided by financing activities
0 0
Effect of exchange rate changes on cash and cash equivalents
0 0
Net change in cash and cash equivalents
3,121 -64,547
Cash and cash equivalents at beginning of period
87,229 -
Cash and cash equivalents at end of period
25,803 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Climb Bio, Inc. (CLYM)

Climb Bio, Inc. (CLYM)